The implantable medical device developer has achieved the first close of a series C round featuring Legend Capital that has a target size of $30m.
US-based medical device producer Axonics Modulation Technologies has received $14.5m in series C funding from investors including Legend Capital, an investment arm of diversified conglomerate Legend Holdings.
Edmond de Rothschild Investment Partners, Advent Life Sciences, Cormorant Asset Management, NeoMed Management and assorted private investors also contributed to the round, which has a target size of $30m.
Incorporated in 2013, Axonics is working on small, implantable medical devices with technology licensed from Alfred Mann Foundation with which aims to alleviate urinary…
